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group, there were nine lives saved compared with the
NSAID group with 18 life-years gained for each death
avoided. The total cost/life saved with Celecoxib was
25,458,588 pesetas (US $131,909) with a cost/life-year
gained of 1,414,366 pesetas (US $7,328) when compared
with the use of NSAIDs.
CONCLUSIONS: The use of Celecoxib instead of
NSAIDs to treat osteoarthritis will produce a lower inci-
dence of severe G-I complications, thus avoiding deaths.
The cost per life-year gained when using Celecoxib is a
reasonable amount, easily covered by the Spanish NHS.
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OBJECTIVES: To perform an economic evaluation on
the short-term costs of managing edema and hyperten-
sion in COX-2-inhibitor-treated patients with osteoar-
thritis (OA) and hypertension (HTN).
METHODS: Two randomized clinical trials (RCT) in
OA/HTN patients showed a significantly higher inci-
dence of systolic blood pressure (SBP) destabilization
(8.7% to 15.6%; RR  0.61, p  .001), edema (4.8% to
8.5%, RR  0.67, p  0.04), and both SBP/edema (0.6%
to 2.2%; RR  0.28, p  0.003) for rofecoxib 25 mg/day
(n  942) compared to celecoxib 200 mg/day (n  960).
The RCT results were projected onto a typical US man-
aged-care organization (MCO) population using: (1) the
age distribution from a large MCO; (2) age- and gender-
specific prevalence of OA and HTN from US government
data; (3) age-specific incidence of cardiorenal events from
pooled RCT data, and (4) prevalence of COX-2 inhibitor
use in a large insurer. We determined resource utilization
and treatment patterns from the published literature and
an expert physician panel. Costs were obtained from
standardized databases and published literature.
RESULTS: For a population of 1,000,000 MCO mem-
bers, 8% of members (n  79,903) are projected to have
OA and HTN, while 2.2% of members (n  21,594) have
OA /HTN and use a COX-2 inhibitor. From the analysis,
the number of additional events predicted to occur with
rofecoxib (relative to celecoxib) are: SBP destabilization
(n  1144); edema-alone (n  453); edema and SBP de-
stabilization (n  345). The total cost savings of treat-
ment with celecoxib would be $474,007. Translated into
other parameters, the cost savings from the celecoxib us-
age would be $1.83 in per patient per month costs, and
$0.24 in the daily cost of COX-2 inhibitor use for an av-
erage patient.
CONCLUSION: The short-term management of SBP de-
stabilization and edema adds to the cost of rofecoxib treat-
ment, relative to celecoxib. Clinicians and payers should
not ignore the clinical effects and economic impact of ar-
thritis medications on blood pressure and edema.
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RA is a chronic disease that affects 0.5 to 1% of the pop-
ulation. The economic impact of RA on individuals and
society is enormous and the costs of RA rise steeply with
disease severity. A therapy that reduces disease progres-
sion could be expected to lead to reductions in resource
use as well as maintaining quality of life.
OBJECTIVE: To estimate the costs and consequences of
adding infliximab to the care of patients with severe rheuma-
toid arthritis (RA) already being treated with methotrexate.
METHODS: Estimates of the impact of infliximab on dis-
ease progression were obtained from the ATTRACT trial
in which 428 RA patients were randomly assigned to
methotrexate or methotrexate plus infliximab. Since pa-
tients in the ATTRACT trial were followed for only 54
weeks, we developed a Markov model in order to estimate
the long-term consequences of RA. The model was based
on a cohort (ARAMIS) involving 4258 consecutively en-
rolled RA patients followed in nine centres in USA and
Canada. Markov health states were based on the Health
Assessment Questionnaire and on drug treatment. For the
first year, costs were calculated using the resource utiliza-
tion by UK patients in the ATTRACT trial and applying
UK unit costs. Long-term costs were obtained from the
Norfolk Arthritis Register (NOAR) cohort. Utilities were
based on visual analogue scale assessments in ATTRACT
(first year) and ARAMIS (long-term).
RESULTS: In the base-case analysis, the incremental cost
per QALY of infliximab was £33,618. Assuming radio-
graphic stabilization of joint disease for patients treated
with infliximab after the first year of treatment (as sug-
gested in the long-term data from the ATTRACT trial)
the cost-effectiveness ratio falls to £5111 per QALY. Sen-
sitivity analyses were performed to allow for uncertainty
in some of the estimates.
CONCLUSION: Infliximab is likely to be a cost-effective
treatment for patients suffering from severe RA.
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OBJECTIVES: To examine the disability and resource
utilisation associated with osteo- and rheumatoid arthri-
tis in five European countries.
METHODS: A large international database was exam-
ined to evaluate the disability and resource use in patients
with rheumatoid and osteo-arthritis. The database in-
cluded the Health Assessment Questionnaire (HAQ) Dis-
ability Index, questions on satisfaction and questions on
resource utilisation and lost work time.
RESULTS: The Arthritis Disease Specific Programme,
held by Adelphi Ltd, was used as the database for this
study. It contains 4580 patient records, 4203 of which
have self-reported HAQ data. HAQ data are reported for
France (n  609), Germany (n  1079), Italy (n  796),
Spain (n  1229), and the UK (n  490). Patients with
rheumatoid arthritis (n  2022) consistently demonstrate
more disability than those with osteoarthritis (n  1836)
(HAQ DI: 1.03 vs 1.01, respectively). Patients in the UK
had the most RA and OA disability (HAQ DI 1.60 and
1.20, respectively). Within disease diagnoses, females had
greater disability (1.08 vs 0.90 RA; 1.05 vs 0.95 OA). Pa-
tients with RA tend to have more GP and specialist visits
over six months compared to those with OA (3.30 and
1.79 vs 3.26 and 1.41), although OA patients tend to
have more ED visits (0.14 vs 0.07). Self-reported days off
work over six months were also greater for RA patients
(25.44 vs 20.24). The greatest work absences were seen
in the UK (RA: 45.00; OA: 41.10) and the least days off
work were seen in Italy (RA: 7.09; OA: 4.24).
CONCLUSIONS: OA and RA have large impacts on dis-
ability and resource utilization in the European countries
we examined. Although debilitating, the extent to which
resources are consumed and work lost varies greatly from
country to country. From this cross-sectional interna-
tional database, RA patients have greater disability com-
pared to OA. This is reflected by higher disability, greater
resource utilisation, and more days off work.
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OBJECTIVE: To examine the reliability and validity of a
new French questionnaire assessing patient satisfaction
with their osteoarthritis (OA) treatment.
METHODS: Item generation: Semi-structured interviews
were performed among 20 osteoarthritis (OA) patients and
10 clinicians. Interviews were recorded, transcribed and an-
alyzed. Content validity and cognitive debriefing of the first
version of the Arthritis Treatment Satisfaction (ARTS) ques-
tionnaire was evaluated by 10 OA patients. Validation
study: Principal component analysis, multi-trait analysis, in-
ternal consistency (Cronbach’s alpha) and known-group va-
lidity were performed on a cross-sectional sample of 797
OA patients. Test-retest was assessed on 133 clinically sta-
ble OA patients. Test-retest reliability was estimated with
the Intraclass Correlation Coefficient (ICC).
RESULTS: Patients were on average 67.5 years old (SD 
10.4), 64.5% were women, 26% had OA of the hip,
58% had OA of the knee, and all patients had suffered
from OA for an average of 7 years (SD  6.4). The re-
sulting ARTS questionnaire comprised 18 items consist-
ing of a clear four dimensional structure measuring
advantages of treatment, treatment convenience, appre-
hensions about treatment and satisfaction with medical
care. Scores were calculated using the mean of items in
each dimension. Cronbach’s alpha ranged from 0.63 for
treatment convenience to 0.86 for advantages of treat-
ment. ICC ranged from 0.61 for advantages of treatment
to 0.75 for treatment convenience. ARTS significantly
differentiated patients according to the presence of side
effects, regular practice of physical activity, perceived
pain and indices of severity.
CONCLUSION: Results provide evidence for the good psy-
chometric properties of this first treatment-satisfaction ques-
tionnaire specific to osteoarthritis. The responsiveness of the
ARTS questionnaire over time is still to be documented.
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OBJECTIVE: To evaluate the economic efficiency of
management guidelines for corticosteroid-induced os-
teoporosis and establish whether it is more economically
efficient to modify the guidelines when targeting respira-
tory patients.
METHODS: Data were collected from GP medical
records related to osteoporosis risk factors and cortico-
steroid use in the previous year. Sample data were used
for economic modelling based on population data and
costs from literature. Three strategies were evaluated: the
existing guidelines; modified guidelines; treatment with-
out reference to guidelines. Main outcome measures were
net discounted cost per fracture averted and net dis-
counted cost per quality adjusted life year (QALY) saved.
RESULTS: A cohort of 110 (71 women) adult patients
prescribed oral and/or inhaled corticosteroids was identi-
fied. Following existing guidelines averted 0.5 fractures
and saved 0.1 QALYs at a net total cost of £5,943. The
resultant cost per fracture averted is £12,506 and cost per
QALY saved is £40,356. When modified, to include in-
termittent oral and inhaled corticosteroid use as risk fac-
tors, the net total costs increased to £30,190, with 3.6
fractures averted and 1.1 QALYs saved resulting in a cost
per fracture averted of £8,419 and cost per QALY saved
of £27,854, representing greater economic efficiency. Fur-
